News Page

AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS)
Subscribe to the AIDSinfo At-a-Glance
e-newsletter to receive regular updates on the latest in HIV/AIDS treatment, prevention, and research.
  • March 10 is National Women and Girls HIV/AIDS Awareness Day

    Each year, March 10 is set aside to observe National Women and Girls HIV/AIDS Awareness Day. The purpose of this day is to recognize the impact of HIV on women and girls and encourage action to reduce the burden of HIV/AIDS among women and girls. According to the Centers for Disease Control and Prevention (CDC), at the end of 2010, 1 in 4 people living with a diagnosis of HIV infection in the United States were women. 

    Explore our National Women and Girls HIV/AIDS Awareness Day webpage [en español] to learn more about the annual observance and to find HIV/AIDS-related information specific to women and girls.

  • FDA Updates Darunavir (Prezista) Labeling

    “On April 7, 2014, FDA approved new changes to the Prezista (darunavir) label to update the following sections:

    • “WARNING AND PRECAUTIONS, Severe Skin Reactions,  ADVERSE REACTIONS, Postmarketing Experience, and PATIENT COUNSELING INFORMATION sections of the labeling were updated with information regarding rash with eosinophilia and systemic symptoms.
    • “DRUG INTERACTIONS, Established and Other Potentially Significant Drug Interaction and CLINICAL PHARMACOLOGY, Table 15 subsections of the labeling were updated with information regarding dolutegravir. …
    • “CLINICAL PHARMACOLOGY, Microbiology subsection of labeling was updated to rilipivirine to the list of drugs that did not show antagonism with darunavir. 
    • “Prezista 400 mg tablets were removed from the HOW SUPPLIED/STORAGE AND HANDLING section because this dosage strength is no longer marketed in the US.”

    The revised label is available at the FDA website.

    More information is available:

  • March 20 is National Native HIV/AIDS Awareness Day
    March 20 is National Native HIV/AIDS Awareness Day—an annual observance that highlights the impact of HIV/AIDS on American Indian, Alaska Native, and Native Hawaiian communities.

    According to the Centers for Disease Control and Prevention (CDC), approximately 20% of HIV-infected people in the United States do not know that they are infected; however, among American Indians and Alaska Natives the figure is closer to 25%. Compared to members of other ethnic or racial groups, American Indians and Alaska Natives who receive a diagnosis of HIV infection or AIDS have one of the shortest survival times. This may be due to HIV infections diagnosed late in the course of the disease or limited access to health care.

    Visit our National Native HIV/AIDS Awareness Day page [en español] to learn how the HIV/AIDS epidemic is affecting native communities.
  • Recent HIV/AIDS News from NIAID
    • April 3, 2014: Future HIV Vaccine Research Must Consider Both Protective Immune Responses and Those That Might Increase Susceptibility to Infection

      “Last year, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, held a scientific meeting to examine why certain investigational HIV vaccines may have increased susceptibility to HIV infection. In a new perspectives article appearing in the journal Science, HIV research leaders from NIAID (Anthony S. Fauci, M.D., and Carl W. Dieffenbach, Ph.D.) and its grantees at Emory University (Eric Hunter, Ph.D.) and the University of California, San Francisco (Susan Buchbinder, M.D.), summarize the findings and considerations for future HIV vaccine research.”

       
    • March 31, 2014: HIV-Infected Men at Increased Risk for Heart Disease, Large Study Finds

      “The buildup of soft plaque in arteries that nourish the heart is more common and extensive in HIV-infected men than HIV-uninfected men, independent of established cardiovascular disease risk factors, according to a new study by National Institutes of Health grantees. The findings suggest that HIV-infected men are at greater risk for a heart attack than their HIV-uninfected peers, the researchers write in Annals of Internal Medicine.”
  • FDA Updates Raltegravir (Isentress) Labeling

    “On April 8, 2014 FDA approved updates to the Isentress (raltegravir) label to include information regarding co-adminsitration of raltegravir with boceprevir or telaprevir.

    “In drug interaction studies, raltegravir did not have a clinically meaningful effect on the pharmacokinetics of telaprevir or boceprevir. No dose adjustment is required for Isentress or boceprevir or telaprevir.”

    The revised label is available at the FDA website.

    More information is available:

  • Updated HHS Perinatal Antiretroviral Treatment Guidelines Released

    The HHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission announces the release of the updated Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States.

    For a complete preview of key updates to the guidelines, please see What's New in the Guidelines. Additions and revisions are also highlighted in yellow throughout the text and tables of the guidelines.

    To view or download the guidelines, go to the Perinatal Guidelines section of AIDSinfo. Separate PDF files of the tables or recommendations can also be downloaded from the page.

    Your Feedback Is Welcome

    Feedback on the latest revisions to the Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States is welcome. Please send your comments with the subject line “Comments on Perinatal Guidelines” to ContactUs@aidsinfo.nih.gov by April 11, 2014.